VolitionRX Ltd (VNRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances

By Yahoo! Finance   |   2 weeks ago
VolitionRX Ltd (VNRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances

The Lyon study shows promise for cancer testing. Plans for prospective studies are in place for potential adoption in national screening programs in France and Taiwan. Quarterly sales trends were affected by customer buying patterns, with growth expected in 2025 through automation and licensing deals.

Read More

Did you find this insightful?